Baidu Venture Capital
Major investor, old shareholder
Yu Tai investment, volcanic capital.
Continue to increase investment. The introduction of two rounds of heavy money fully proves that the capital market recognizes Enze Kangtai's forward-looking strategic layout and continuous innovation ability in the exocrine track, and will also accelerate the enterprise to become a new leading enterprise with first-Mover advantage in the exocrine field.
In the research of exosomes translational medicine, Enze Kangtai has spent more than four years continuously polishing and iterating exosomes technical service products, forming a rich product line, such as multidisciplinary solutions with exosomes as the core competitiveness in Qualcomm and translational medicine research solutions with exosomes engineering transformation and mass production as the core competitiveness, involving more than 30 products and services.
Enze Kangtai mainly cooperates with clinical experts and biological enterprises to carry out scientific research. At present, Enze Kangtai has established cooperation with more than 100 well-known top three hospitals and scientific research units in China, and achieved a series of important achievements: more than 80 SCI papers have been published, and 16 invention patents have been applied. Five new technologies and new products have been recognized by Beijing, participated in writing exosomes expert knowledge, and cooperated with the research and application committee of extracellular vesicles in China research hospitals. In the future, Enze Kangtai will continue to pay attention to the latest frontier research of exosomes, go deep into the underlying technology development, and continue to export the best exosomes technical service solutions.
For this financing,
Kong Guan Yi, CEO of Enze Kangtai
Express: I am very grateful to the new and old shareholders for their recognition and support. Since its establishment four years ago, Enze Kangtai has always adhered to the corporate mission of promoting medical development and benefiting a better life with biotechnology, devoted itself to exocrine technology research and clinical transformation, and built an exocrine transformation medical platform with core competitiveness and an exocrine drug-carrying platform with independent intellectual property rights to continuously promote the development of the industry. At present, the company mainly covers two business directions: translational medicine research services based on exosomes and innovative drug research and development based on exosomes. The company has accumulated a stable core team, formed a data-driven rapid iterative work style and values of altruism, diligence, responsibility, trust, eternal love and embrace of change, which laid a solid foundation for the company's rapid development in the future. This round of financing will help the company build a better platform for research and transformation of engineering exosomes.
Zhang Zihao, Investment Manager of Baidu Venture Capital
Expression: Exosomes are regarded as new clinical markers of many diseases, such as tumors, and are also expected to become new engineering drug delivery carriers, which have attracted much attention in recent years. Globally, the engineering foreign body pipeline has entered the early stage of clinical development. Enze Kangtai entered the track earlier in China, and has a talented team with pragmatic style and rich professional experience. At present, the construction of engineering exocrine innovation platform and the layout of core patent technology have been completed, and the industry position advantage is outstanding. I hope that the participation of Baidu Venture Capital can help the company to promote the research and development of related products and promote the development of the company and even the field.
Dr. Ji, founder and general manager of investment
Expression: As a new drug delivery carrier, exosomes have good biocompatibility, low immunogenicity, and can penetrate the biological barrier, which can be targeted in engineering and has great potential for future development. As the head enterprise of exocrine research and development at home and abroad, Enze Kangtai's core team members have in-depth research in bioinformatics and biochemistry, and have maintained close cooperation with exocrine industry associations, which has a prominent position in the industry. Its extracellular engineering transformation platform is based on independent intellectual property rights, which can realize the external loading or internal loading of target protein through scaffold protein, and can efficiently carry target protein fragments and nucleic acid sequences. With the start of its Daxing GMP pilot plant, it will certainly promote the great progress of its product pipeline and realize the early listing of products.
This article is original for the investment community. When reprinting the webpage, the source, the name of the investment community and the author must be indicated at the beginning of the article. Reprinted by WeChat, you must contact authorization in the original comment area of WeChat. Illegal reprinting must be investigated.